Literature DB >> 33888034

Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Antonio Cigliano1, Xin Chen2, Diego F Calvisi3.   

Abstract

AREAS COVERED: This review provides an overview regarding the current scenario and knowledge of the CCA genomic landscape and the potentially actionable molecular aberrations in each CCA subtype. EXPERT OPINION: The establishment and advances of high-throughput methodologies applied to genetic and epigenetic profiling are changing many cancer types' therapeutic landscape , including CCA.The large body of data generated must be interpreted appropriately and eventually implemented in clinical practice. The following advancements toward precision medicine in CCA management will require designing better clinical trials with improved methods to stratify biliary tumor patients.

Entities:  

Keywords:  Cholangiocarcinoma; driver mutations; epigenetics; genomic landscape; molecular pathogenesis; molecular profiling; next-generation sequencing; precision medicine; predictive biomarkers; targeted therapies

Mesh：

Substances：

Year:  2021        PMID： 33888034      PMCID： PMC8173760          DOI： 10.1080/17474124.2021.1915128

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN： 1747-4124            Impact factor:   3.869


  156 in total

1.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

2.  Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct.

Authors:  Ching-Yao Yang; Wei-Ju Huang; Jia-Huei Tsai; Arkady Cheng; Chih-Chi Chen; Hung-Pin Hsu; Yung-Ming Jeng
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

3.  MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes.

Authors:  Chiara Braconi; Nianyuan Huang; Tushar Patel
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

4.  Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Authors:  Farshad Farshidfar; Siyuan Zheng; Marie-Claude Gingras; Yulia Newton; Juliann Shih; A Gordon Robertson; Toshinori Hinoue; Katherine A Hoadley; Ewan A Gibb; Jason Roszik; Kyle R Covington; Chia-Chin Wu; Eve Shinbrot; Nicolas Stransky; Apurva Hegde; Ju Dong Yang; Ed Reznik; Sara Sadeghi; Chandra Sekhar Pedamallu; Akinyemi I Ojesina; Julian M Hess; J Todd Auman; Suhn K Rhie; Reanne Bowlby; Mitesh J Borad; Andrew X Zhu; Josh M Stuart; Chris Sander; Rehan Akbani; Andrew D Cherniack; Vikram Deshpande; Taofic Mounajjed; Wai Chin Foo; Michael S Torbenson; David E Kleiner; Peter W Laird; David A Wheeler; Autumn J McRee; Oliver F Bathe; Jesper B Andersen; Nabeel Bardeesy; Lewis R Roberts; Lawrence N Kwong
Journal:  Cell Rep       Date:  2017-06-27       Impact factor: 9.423

Review 5.  Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?

Authors:  Chiara Braconi; Stephanie Roessler; Beata Kruk; Frank Lammert; Marcin Krawczyk; Jesper B Andersen
Journal:  Liver Int       Date:  2019-03-24       Impact factor: 5.828

6.  SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.

Authors:  Maite Merino-Azpitarte; Elisa Lozano; María J Perugorria; Aitor Esparza-Baquer; Oihane Erice; Álvaro Santos-Laso; Colm J O'Rourke; Jesper B Andersen; Raúl Jiménez-Agüero; Adelaida Lacasta; Mauro D'Amato; Óscar Briz; Nidhi Jalan-Sakrikar; Robert C Huebert; Kristen M Thelen; Sergio A Gradilone; Ana M Aransay; José L Lavín; Maite G Fernández-Barrena; Ander Matheu; Marco Marzioni; Gregory J Gores; Luis Bujanda; José J G Marin; Jesús M Banales
Journal:  J Hepatol       Date:  2017-02-22       Impact factor: 25.083

Review 7.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

8.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

9.  HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.

Authors:  Joon Ho Wang; Eun Jeoung Lee; Meiying Ji; Seon Mee Park
Journal:  Oncol Rep       Date:  2018-05-16       Impact factor: 3.906

10.  Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers.

Authors:  Waraporn Chan-On; Maarja-Liisa Nairismägi; Choon Kiat Ong; Weng Khong Lim; Simona Dima; Chawalit Pairojkul; Kiat Hon Lim; John R McPherson; Ioana Cutcutache; Hong Lee Heng; London Ooi; Alexander Chung; Pierce Chow; Peng Chung Cheow; Ser Yee Lee; Su Pin Choo; Iain Bee Huat Tan; Dan Duda; Anca Nastase; Swe Swe Myint; Bernice Huimin Wong; Anna Gan; Vikneswari Rajasegaran; Cedric Chuan Young Ng; Sanjanaa Nagarajan; Apinya Jusakul; Shenli Zhang; Priya Vohra; Willie Yu; DaChuan Huang; Paiboon Sithithaworn; Puangrat Yongvanit; Sopit Wongkham; Narong Khuntikeo; Vajaraphongsa Bhudhisawasdi; Irinel Popescu; Steven G Rozen; Patrick Tan; Bin Tean Teh
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 41.307
View more
  1 in total

1.  Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells?

Authors:  Juan Wang; Emilien Loeuillard; Gregory J Gores; Sumera I Ilyas
Journal:  Expert Opin Ther Targets       Date:  2021-12-03       Impact factor: 6.797
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.